KLRS - NASDAQ

KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.72

-3.7%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$88.28M
EPS-2.8500
P/E Ratio-1.66
Earnings Date08/12/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

KT

Kalaris Therapeutics Inc Earnings Call Transcripts

KLRS · NASDAQ

2012

3
Q2
Aug 2
Q3
Nov 14
Q4
Mar 4
Q1
N/A

2010

1
Q1
May 4
Q2
N/A
Q3
N/A
Q4
N/A

2009

1
Q4
Feb 3
Q1
N/A
Q2
N/A
Q3
N/A

2007

2
Q1
May 2
Q3
Oct 31
Q2
N/A
Q4
N/A

Related Guides

Blog Categories

Continue your KLRS research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.